published plots of estimated versus measured GFR reveals a very wide scatter suggesting that applying these formulae to individuals may not give the required precision for estimated GFR. The authors quote a study by Froissart et al. 2 in which the sensitivity and speci¢city of the MDRD formula to detect patients with a GFR of less than 60 mL/min/1.73 m 2 (stage 3 chronic kidney disease or worse) are 93% and 88%, respectively. From the data quoted by Lamb et al., 1 the prevalence of individuals in a general population with a GFR of less then 60 mL/ min/1.73 m 2 can be estimated as 4.7% (the sum of 4.3 + 0.2 + 0.2, taken from Table 1 ). Using these ¢gures, the positive predictive value of an estimated GFR below 60 mL/min/1.73 m 2 (that is the percentage of individuals with an estimated GFR below this value who actually have kidney disease) can be calculated as 28%. Therefore, the number of false positives (11.4%) outnumber the number of true positives (4.4%) by approximately 2.6:1; and the prevalence of renal disease one can actually expect to ¢nd in the population by using derived GFR will be grossly exaggerated at 11.4 + 4.4 ¼15.8%, which will have a major impact on clinical services.
Furthermore, Froissart et al. 2 quote the SD of the mean di¡erence between estimated and measured GFR as 13.5 mL/min/1.73 m 2 when using the 4-v-MDRD formula. Therefore, the 95% con¢dence limits of the di¡erence between measured and estimated GFR is 71.95 Â13.5 ¼ 726 mL/min/1.73 m 2 . In other words, the estimated GFR is likely to fall within 726 mL/min/1.73 m 2 of the measured GFR, and at the cut-o¡ of 60 mL/min/1.73 m 2 for stage 3 kidney disease, the estimated value is likely to fall anywhere within the range 34--86 mL/min/1.73 m 2 .
These limitations need to be carefully considered before introducing estimated GFR into routine clinical practice. The poor precision of individual estimates of GFR is a consequence of the variables used (age, sex and ethnicity) being poor predictors of the muscle mass of any one individual, a limitation that is unlikely to be resolved by improving the performance of serum creatinine assays.
Although the general practice data has a prevalence similar to that expected, the other patient sources have a higher degree of renal impairment. This is probably due to bias in those people who have blood tests (i.e. those tested tend to be older and more ill than the general population). There will be more people who have diabetes, jaundice, ketosis or sepsis in the tested group than in the untested group. Such conditions can potentially result in a positive bias in creatinine measurement and thus would result in a lower estimate of GFR. However, at the end of 2002, the general chemistry analysers were changed (Beckman CX7 to Olympus AU-640) but there was no signi¢cant shift in observed prevalences, indicating no signi¢cant inter-assay bias shift. We acknowledge the limitations of the MDRD equation when acute renal impairment develops and shall be examining this data in due course to make allowances for this. This is important because one potential use of eGFR is its use in drug dosing, for example in low molecular weight heparins such as Clexane.
It is important that laboratories are aware that overall population prevalences should not be used to predict the service outcomes of introduction of calculated GFR because the observed rates in routine clinical practice may be signi¢cantly higher. Disease study (4-v MDRD) is attractive since the only additional information required is the patient's age, sex and ethnicity. However, I would urge caution at trying to extrapolate ¢ndings based on population studies to individual patients. Simple inspection of published plots of estimated versus measured GFR reveals a very wide scatter suggesting that applying these formulae to individuals may not give the required precision for estimated GFR. The authors quote a study by Froissart et al. 2 in which the sensitivity and speci¢city of the MDRD formula to detect patients with a GFR of less than 60 mL/min/1.73 m 2 (stage 3 chronic kidney disease or worse) are 93% and 88%, respectively. From the data quoted by Lamb et al., 1 the prevalence of individuals in a general population with a GFR of less then 60 mL/ min/1.73 m 2 can be estimated as 4.7% (the sum of 4.3 + 0.2 + 0.2, taken from Table 1 ). Using these ¢gures, the positive predictive value of an estimated GFR below 60 mL/min/1.73 m 2 (that is the percentage of individuals with an estimated GFR below this value who actually have kidney disease) can be calculated as 28%. Therefore, the number of false positives (11.4%) outnumber the number of true positives (4.4%) by approximately 2.6:1; and the prevalence of renal disease one can actually expect to ¢nd in the population by using derived GFR will be grossly exaggerated at 11.4 + 4.4 ¼15.8%, which will have a major impact on clinical services.
